万邦德：子公司WP107药品获得美国FDA新药临床试验许可

Core Viewpoint - Wanbangde's subsidiary has received FDA approval for clinical trials of WP107, a treatment for generalized myasthenia gravis, indicating a significant advancement in the company's drug development pipeline [1]. Group 1 - Wanbangde's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received notification from the FDA on January 15, 2025 [1]. - The clinical trial application for WP107 (Huperzine A oral solution) has been approved for the treatment of generalized myasthenia gravis [1].